ReviewMaterials (Basel, Switzerland)2026
Generation of Human Bioartificial Tissues Using Agarose-Derived Biomaterials.
Review in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Agarose is a thermoreversible, highly biocompatible polysaccharide increasingly used in tissue engineering (TE). Its molecular architecture, optical clarity, tunable mechanics, and chemical inertness make agarose hydrogels attractive scaffolds for generating bioartificial tissues by TE. This review summarizes current knowledge on agarose extraction, purification, structural variants, and physicochemical properties regarding gelation behavior, stiffness, porosity, and bioactivity. We discuss how agarose type and concentration critically determine hydrogel biomechanical and optical performance, influencing cell behavior and in vivo suitability. Although biologically inert, agarose can be functionalized or combined with fibrin, collagen, chitosan, and other biomaterials to enhance cell adhesion, proliferation, and differentiation. Diverse biofabrication approaches-including micromolding, bead production, 3D bioprinting, and de novo assembly of cells, biomaterials and bioactive factors-have enabled the generation of microtissues, organoids, and complex multilayered constructs. Agarose-based biomaterials allowed for the successful generation of bioartificial substitutes of cartilage, bone, adipose tissue, skin, cornea, oral mucosa, and the peripheral nerve, with several fibrin-agarose advanced therapy medicinal products (ATMP) already reaching clinical application, including the skin substitute UGRSKIN, the artificial cornea NANOULCOR and the palate mucosa BIOCLEFT. Together, current evidence positions agarose as a versatile and translationally relevant biomaterial for next-generation TE, warranting further exploration of its potential in additional therapeutic contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.